Johnson & Johnson (JNJ) Return on Assets (ROA): 10.47%
Is Johnson & Johnson’s return on assets (ROA) high or low?
Johnson & Johnson's return on assets (ROA) of 10.47% is 12% below its 5-year average of 11.95%, near the low end of its 5-year range (7.81%–20.98%).
As of Thursday, June 11, 2026. 1.55% below its 12-month average of 10.63%.
JNJ Return on Assets (ROA) Chart
JNJ Average Return on Assets (ROA) Chart
JNJ Current vs Average Return on Assets (ROA) Chart
JNJ Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
10.47%
RETURN ON ASSETS (ROA) AVG TTM
10.63%
RETURN ON ASSETS (ROA) AVG 3Y
12.96%
RETURN ON ASSETS (ROA) AVG 5Y
11.95%
RETURN ON ASSETS (ROA) AVG 10Y
10.49%
RETURN ON ASSETS (ROA) AVG 15Y
10.55%
RETURN ON ASSETS (ROA) AVG 20Y
11.56%
CURRENT VS TTM AVG
-1.55%
CURRENT VS 3Y AVG
-19.18%
CURRENT VS 5Y AVG
-12.38%
CURRENT VS 10Y AVG
-0.18%
CURRENT VS 15Y AVG
-0.72%
CURRENT VS 20Y AVG
-9.43%
JNJ Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 10.47% | 10.63% | 12.96% | 11.95% |
| Pfizer Inc. (PFE) | $149.61B | 3.61% | 3.75% | 6.08% | 7.08% |
| Merck & Co., Inc. (MRK) | $298.23B | 6.94% | 13.98% | 10.40% | 10.28% |
| AbbVie Inc. (ABBV) | $399.86B | 2.67% | 3.16% | 4.61% | 4.90% |
| Eli Lilly and Company (LLY) | $1.10T | 21.68% | 15.90% | 13.15% | 12.89% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 8.41% | -0.92% | 3.28% | 1.99% |
Asset Efficiency
ROA
10.5%
ROE
25.9%
Johnson & Johnson Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Johnson & Johnson (JNJ)?
- The return on assets (ROA) for JNJ stock is 10.47%.
- Is Johnson & Johnson's return on assets (ROA) high or low?
- Johnson & Johnson's return on assets (ROA) of 10.47% is 12% below its 5-year average of 11.95%, near the low end of its 5-year range (7.81%–20.98%).
- What is the TTM average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The TTM average return on assets (ROA) for JNJ stock is 10.63%.
- What is the 3Y average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The 3Y average return on assets (ROA) for JNJ stock is 12.96%.
- What is the 5Y average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The 5Y average return on assets (ROA) for JNJ stock is 11.95%.
- What is the 10Y average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The 10Y average return on assets (ROA) for JNJ stock is 10.49%.
- What is the 15Y average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The 15Y average return on assets (ROA) for JNJ stock is 10.55%.
- What is the 20Y average return on assets (ROA) for Johnson & Johnson (JNJ)?
- The 20Y average return on assets (ROA) for JNJ stock is 11.56%.
Johnson & Johnson Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-28 | 13.46% |
| 2024-12-29 | 7.81% |
| 2023-12-31 | 20.98% |
| 2023-01-01 | 9.57% |
| 2022-01-02 | 11.47% |
| 2021-01-03 | 8.41% |
| 2019-12-31 | 9.59% |
| 2018-12-31 | 10.00% |
| 2017-12-31 | 0.83% |
| 2016-12-31 | 11.71% |
| 2015-12-31 | 11.55% |
| 2014-12-31 | 12.52% |
| 2013-12-31 | 10.42% |
| 2012-12-31 | 8.94% |
| 2011-12-31 | 8.51% |
| 2010-12-31 | 12.96% |
| 2009-12-31 | 12.95% |
| 2008-12-31 | 15.25% |
| 2007-12-31 | 13.06% |
| 2006-12-31 | 15.67% |
| 2005-12-31 | 17.09% |
| 2004-12-31 | 15.34% |
| 2003-12-31 | 14.91% |
| 2002-12-31 | 16.27% |
| 2001-12-31 | 14.73% |
| 2000-12-31 | 14.46% |
| 1999-12-31 | 14.65% |
| 1998-12-31 | 11.00% |
| 1997-12-31 | 15.40% |
| 1996-12-31 | 14.43% |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato